Subtitle
Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.
Subtitle
Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.
Proto therapy Time
May 2021
Executive summary
This study reported outcomes of 45 patients with stage III NSCLC treated with PBT of 74 GyE and concurrent chemotherapy. With a median follow-up time of 42.1 months for all patients, the 3- and 5-year OS rates were 63.7% and 38.8%, and the median overall survival was 49.1 months. No grade 4 or 5 acute or late non-hematologic toxicities were observed.
Top cancer treatments
Related contents
Proton Therapy Publication
April 2024
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
Proton Therapy Publication
November 2023
Proton Therapy Mediates Dose Reductions to Brain Structures Associated with Cognition in Children with Medulloblastoma.
Proton Therapy Publication
October 2023
Radiation-induced skin and heart toxicity in patients with breast cancer treated with adjuvant proton radiotherapy: a comparison with photon radiotherapy.
Proton Therapy Publication
September 2023
Ultra-High Dose-Rate Proton FLASH Improves Tumor Control.
Proton Therapy Publication
June 2023
The current status of FLASH particle therapy: a systematic review.
Proton Therapy Publication
May and June 2023
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Proton Therapy Publication
April 2023
Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR).
Proton Therapy Publication
March 2023
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Proton Therapy Publication
November 2022
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.